|Bid||28.45 x 0|
|Ask||29.01 x 0|
|Day's range||28.29 - 28.51|
|52-week range||15.20 - 28.79|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Here's why AstraZeneca agreed to pay Daiichi Sankyo another enormous sum to develop and commercialize an experimental cancer drug.
The British drugmaker has been bolstering its portfolio of cancer therapies, particularly ADCs, a major area of focus for the company as it also ploughs on with its coronavirus vaccine candidate. AstraZeneca said on Monday it would make staggered upfront payments totalling $1 billion to Daiichi for an experimental drug called DS-1062, which belongs to a promising class of therapies called antibody drug conjugates (ADC). The deal will not affect 2020 earnings forecast, AstraZeneca said.
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062